Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based

[News]

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

More... (http://www.news-medical.net/news/20110107/Intrexon-Corporation-ZIOPHARM-enter-partnership-to-develop-commercialize-DNA-based-therapeutics.aspx)